Rosebay Willowherb: What the Evidence Actually Shows About Uses, Dosage, and Safety

1.5K

Rosebay willowherb (Epilobium angustifolium, also placed in the genus Chamaenerion) is a tall, magenta-flowered plant best known today for one purpose: easing the urinary symptoms that come with an enlarged prostate. The European Medicines Agency lists it as a traditional herbal medicine for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH), based on long-standing use rather than full pharmaceutical trials [EMA, 2015]. A small but well-conducted 2021 randomised trial added the first solid human evidence behind that traditional use [Esposito, 2021].

Older herbals describe rosebay willowherb mainly as a digestive astringent. Modern research tells a different story. The plant’s most-studied compound, an ellagitannin called oenothein B, shows effects on inflammation, prostate cells, and microbes in laboratory work [Schepetkin, 2016] — and human trial data, while limited, points in the same direction.

Here is what the evidence supports, what it doesn’t, and how to use the herb safely.

The short answer

Rosebay willowherb tea or extract is most often taken by older men to ease BPH-related symptoms such as frequent urination, weak stream, and waking at night to urinate. The strongest human evidence so far is a single six-month randomised trial of 128 men, which found a standardised extract improved nocturia and reduced post-void residual urine without harming kidney or liver markers [Esposito, 2021]. Other traditional uses — digestive complaints, mouth inflammation, skin care — rest mostly on history and laboratory studies.

Rosebay willowherb is not a cancer treatment, a substitute for a prostate exam, or a replacement for medications such as alpha-blockers or 5-alpha-reductase inhibitors. Any new urinary symptoms in a man over 40 should be evaluated by a clinician first [NIDDK, 2024].

What rosebay willowherb actually is

Rosebay willowherb is a perennial herb native to cool temperate regions across the Northern Hemisphere. In Britain it is “rosebay willowherb”; in North America the same plant is called fireweed because it colonises burned ground after wildfires. The plant grows 0.5 to 2 metres tall, with narrow willow-like leaves and tall spikes of bright pink-to-magenta flowers that bloom in mid to late summer [Kew, 2024].

One detail in older articles is wrong and worth correcting: rosebay willowherb is not a member of the daisy family (Asteraceae). It belongs to the willowherb / evening primrose family, Onagraceae [Kew, 2024].

Botanical identity at a glance

Feature	Detail
Accepted scientific name	Chamaenerion angustifolium (L.) Scop.
Common synonym	Epilobium angustifolium L.
Family	Onagraceae (willowherb / evening-primrose family)
Other names	Fireweed, great willowherb, willow herb, épilobe (FR), epilobio (ES), Weidenröschen (DE)
Habitat	Cool temperate Northern Hemisphere; clearings, roadsides, burned ground
Parts used	Aerial parts (flowering tops, leaves, stems) collected before or during flowering

The active compound: oenothein B

Most of rosebay willowherb’s researched effects trace to a large macrocyclic ellagitannin called oenothein B. The compound makes up roughly 2 to 14 percent of dried aerial-part extracts, depending on harvest time and growing conditions [Schepetkin, 2016], and it is the marker used to standardise commercial supplements.

In laboratory work, oenothein B has reduced inflammatory signalling in human immune cells, slowed the growth of hormone-sensitive prostate cancer cells (LNCaP), and inhibited enzymes such as 5-alpha-reductase and aromatase that play roles in prostate biology [Schepetkin, 2016] [Granica, 2014]. These are mechanistic results in cells and animals, not proof of clinical effect.

What the evidence says

Lower urinary tract symptoms and BPH — the strongest signal

Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate that affects an estimated 50 percent of men by age 60 and around 90 percent by age 85. Typical complaints are slow stream, dribbling, urgency, frequent daytime urination, and waking at night to urinate (nocturia) [NIDDK, 2024].

The European Medicines Agency lists rosebay willowherb (and the closely related E. parviflorum) as a traditional herbal medicine for relief of lower urinary tract symptoms related to BPH, after a clinician has ruled out serious conditions. That designation reflects decades of European use rather than full drug-trial evidence [EMA, 2015].

The strongest human trial to date is a 2021 monocentric, randomised, double-blind, placebo-controlled study by Esposito and colleagues at the University of Naples. The trial enrolled 128 men with BPH and gave them either 500 mg per day of a standardised extract or placebo for six months. After six months, the active group showed a significant drop in post-void residual urine, fewer nocturia episodes, and improvements on the International Prostate Symptom Score (IPSS). No subject reported an adverse event, and liver and kidney markers stayed stable [Esposito, 2021].

This is encouraging but limited. It is one trial, at one centre, funded in part by an extract maker, with a follow-up of six months. Independent replication in larger, multi-centre trials would settle whether the effect is reliable. For comparison, the US National Center for Complementary and Integrative Health notes that saw palmetto, the most-studied herbal option for BPH, has produced mixed results across many trials [NCCIH, 2025]. Read more about saw palmetto in our piece on the palmetto shrub and prostate health, and on stinging nettle, another commonly tried BPH herb.

Antibacterial and antifungal activity (laboratory)

A 2023 systematic review of 23 studies found that E. angustifolium extracts inhibited the growth of both gram-positive and gram-negative bacteria, with stronger activity against gram-positive organisms such as Staphylococcus aureus, and against several dermatophyte fungi [Dreger, 2023]. These results come from petri dishes and skin-cell models, not from people with infections. They are interesting for cosmetic and topical research but should not be read as a reason to substitute the herb for antibiotics.

Anti-inflammatory and antioxidant effects (preclinical)

Across cell and animal studies, E. angustifolium extracts and oenothein B have lowered inflammatory mediators (such as IL-6, IL-8, prostaglandin E2) and have neutralised reactive oxygen species [Schepetkin, 2016]. These mechanisms plausibly underlie both the BPH effect and the herb’s traditional use for skin and mucous-membrane inflammation, but no large clinical trials have measured inflammation outcomes in humans.

Skin and topical use (early evidence)

A 2022 review summarised dermatological research on rosebay willowherb extracts, including in vitro and small in vivo studies suggesting sebum regulation, antioxidant defence, and reduced redness [Nowak, 2022]. Several cosmetic ingredients (for example “Epispot” and Epilobium-based actives) are now used in over-the-counter creams. This is a reasonable place to try the plant, with the caveat that cosmetic claims are not the same as proof of treating a skin disease.

Traditional digestive and mouth-rinse uses (limited modern data)

Older herbals, including the original article on this site, describe rosebay willowherb as an astringent for diarrhoea, gastroenteritis, and inflamed gums or throat. The plant’s tannins do produce astringent effects, and the EMA assessment notes traditional digestive use in some European pharmacopoeias [EMA AR, 2015]. Modern clinical evidence for these uses is sparse, however. If you have ongoing diarrhoea, our overview of the main causes of diarrhoea is a better starting point than self-treating with herbs; for mouth and throat inflammation, gargles based on better-studied herbs such as garden sage or wayfaring tree decoction are also options.

How rosebay willowherb is taken

Tea (the EMA-recognised preparation)

The EMA traditional-use monograph specifies a herbal tea made from the comminuted (cut) dried aerial parts of E. angustifolium and/or E. parviflorum. The recommended preparation for adults is:

• 1.5 to 2.0 g of the dried herb in 250 ml of boiling water, taken twice daily.
• Not recommended for children or adolescents under 18 years of age.
• Long-term daily use is acceptable provided symptoms are stable and have been evaluated by a clinician.

Source: EMA HMPC herbal monograph on Epilobium angustifolium / parviflorum herba, EMA/HMPC/712511/2014, adopted 24 November 2015. [EMA, 2015]

Note that the 50-gram-per-day dose recommended in some older sources, including the previous version of this article, is far higher than the dose specified by the EMA monograph and is not supported by any clinical document — stay within the 1.5–2.0 g, twice-daily range.

Standardised capsules and extracts

Several European supplement makers now sell capsules standardised to a minimum oenothein B content. The most rigorously tested product, used in the 2021 RCT, delivered 500 mg of standardised E. angustifolium extract daily (standardised to ≥15 percent oenothein B) for six months [Esposito, 2021]. Other capsule products vary widely; pick one that lists the oenothein B percentage on the label and is sold by a company that publishes third-party testing.

Safety, side effects, and who should avoid it

Reported side effects

Rosebay willowherb is well tolerated in published studies. The EMA assessment report and the 2021 trial found no serious adverse events at the recommended doses [EMA AR, 2015] [Esposito, 2021]. Mild digestive upset (nausea or loose stools) can occur, especially with strong infusions, and is consistent with the herb’s tannin content.

Drug and supplement interactions to consider

No specific human drug interaction studies have been published, so any interactions are theoretical and based on mechanism [NCCIH, 2024]. The most relevant considerations are:

• Iron and other minerals — the high tannin content can bind dietary iron and reduce absorption. Take the tea at least one to two hours away from iron supplements or iron-rich meals.
• 5-alpha-reductase inhibitors and alpha-blockers — if you already take finasteride, dutasteride, tamsulosin, or a similar BPH drug, talk to the prescriber before adding willowherb. There is no direct evidence of harmful interaction, but combining therapies for the same indication should be a clinician decision, not a self-care decision.
• PSA testing — the 2021 trial did not show clinically meaningful changes in PSA, but any herb that influences prostate biology can in theory alter the interpretation of PSA screening. Tell your urologist if you are taking it.

Pregnancy, breastfeeding, and children

The EMA states that use during pregnancy and lactation is not relevant because the registered indication (BPH-related urinary symptoms) only applies to men. No reproductive-toxicity data exist for women of childbearing age [EMA, 2015]. Outside the BPH context, rosebay willowherb has not been formally evaluated for safety in pregnancy or breastfeeding and should be avoided.

Children and adolescents under 18 should not use the product [EMA, 2015].

Red-flag urinary symptoms — see a doctor

Rosebay willowherb is intended for mild-to-moderate BPH symptoms after a doctor has confirmed the diagnosis. Stop the herb and get prompt medical care if you develop any of the following, which can signal infection, stones, retention, or cancer:

• Fever or chills with urinary symptoms
• Blood in the urine
• Pain on urination or pain in the lower back, pelvis, or testicles
• Inability to urinate (urinary retention)
• Sudden worsening of symptoms, or new symptoms in a man under 40

[EMA, 2015] [NIDDK, 2024].

For more on prostate and urinary-tract conditions worth distinguishing from BPH, see our overview of urinary system diseases and prevention, the site’s main herbal remedies for urinary support page, and the wider Urinary Health category.

Realistic expectations

If you decide to try rosebay willowherb for mild BPH symptoms, expect a slow, modest effect rather than a dramatic shift. In the 2021 trial, meaningful change appeared around the two-month mark and grew through six months [Esposito, 2021]. A few practical points:

• Give it at least 8 to 12 weeks before judging whether it helps.
• Track symptoms with a simple metric, such as the number of nightly bathroom trips per week, instead of relying on memory.
• Re-evaluate every six months with the clinician who is following your BPH, especially before continuing into a second year of use.
• Stop and seek care if symptoms worsen, not get better — the herb is a comfort measure, not a fix for progressive disease.

Health Disclaimer This article is for general information only and is not medical advice, diagnosis, or treatment. Rosebay willowherb is classified by the European Medicines Agency as a traditional herbal medicine, which means its use is based primarily on long-standing experience rather than full pharmaceutical trial data. Always speak with a qualified clinician — a primary-care doctor, urologist, or pharmacist — before starting any new herb or supplement, especially if you take prescription medications, have a chronic condition, are scheduled for surgery, or are pregnant or breastfeeding. Any new, worsening, or red-flag urinary symptoms — fever, blood in the urine, painful urination, or inability to urinate — need to be evaluated by a clinician, not self-treated.

Frequently Asked Questions

References

1. Committee on Herbal Medicinal Products (HMPC). European Union Herbal Monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba. EMA/HMPC/712511/2014. Adopted 24 November 2015.  → View source
2. HMPC. Final Assessment Report on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba. EMA/HMPC/712510/2014. 24 November 2015.  → View source
3. Esposito C, Santarcangelo C, Masselli R, et al. Epilobium angustifolium L. extract with high content in oenothein B on benign prostatic hyperplasia: a monocentric, randomized, double-blind, placebo-controlled clinical trial. Biomedicine & Pharmacotherapy. 2021;138:111414. doi:10.1016/j.biopha.2021.111414.  → View source
4. Schepetkin IA, Ramstead AG, Kirpotina LN, Voyich JM, Jutila MA, Quinn MT. Therapeutic potential of polyphenols from Epilobium angustifolium (fireweed). Phytotherapy Research. 2016;30(8):1287-1297. doi:10.1002/ptr.5648.  → View source
5. Granica S, Piwowarski JP, Czerwińska ME, Kiss AK. Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): a review. Journal of Ethnopharmacology. 2014;156:316-346. doi:10.1016/j.jep.2014.08.036.  → View source
6. Dreger M, Adamczak A, Foksowicz-Flaczyk J. Antibacterial and antimycotic activity of Epilobium angustifolium L. extracts: a review. Pharmaceuticals. 2023;16(10):1419. doi:10.3390/ph16101419.  → View source
7. Nowak A, Zielonka-Brzezicka J, Perużyńska M, Klimowicz A. Epilobium angustifolium L. as a potential herbal component of topical products for skin care and treatment — a review. Molecules. 2022;27(11):3536. doi:10.3390/molecules27113536.  → View source
8. Christenhusz MJM, Leitch AR, Leitch IJ, et al. The genome sequence of rosebay willowherb Chamaenerion angustifolium (L.) Scop., 1771 (syn. Epilobium angustifolium L., 1753) (Onagraceae). Wellcome Open Research. 2024;9:170. doi:10.12688/wellcomeopenres.21163.1.  → View source
9. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Enlarged Prostate (Benign Prostatic Hyperplasia). U.S. Department of Health and Human Services.  → View source
10. National Center for Complementary and Integrative Health (NCCIH). 5 Tips: What You Should Know About Complementary Health Approaches for BPH. NIH.  → View source
11. NCCIH. Herb-Drug Interactions (Clinical Digest for Health Professionals). NIH.  → View source